1. AbbVie. EPKINLY™ (epcoritamab-bysp) approved by U.S. FDA as the first and only bispecific antibody to treat adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) [media release]. 19 May 2023. https://www.abbvie.com.
2. Genmab US, Inc. EPKINLY™ (epcoritamab-bysp) injection, for subcutaneous use: US prescribing information. 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761324Orig1s000lbl.pdf. Accessed 21 June 2023.
3. Engelberts PJ, Hiemstra IH, de Jong B, et al. DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing. EBioMedicine. 2020;52: 102625.
4. AbbVie. AbbVie receives positive CHMP opinion for epcoritamab (TEPKINLY®) for the treatment of adults with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) [media release]. 21 July 2023. http://www.abbvie.com
5. Genmab. Genmab announces submission of Japan New Drug Application (JNDA) for epcoritamab (DuoBody®-CD3xCD20) for the treatment of relapsed/refractory large B-cell lymphoma (LBCL) [media release]. 21 December 2022. http://www.genmab.com.